Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Children With Visual Pathway Glioma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 07 May 2009 According to a Burzynski Research media release, the FDA responded to the questions in the Briefing Package and thereafter cancelled the meeting on May 7, 2009.
- 07 May 2009 Interim results in 16 patients reported in a Burzynski Research media release.
- 07 May 2009 According to a Burzynski Research media release, results have been presented to the FDA in the Request for End of Phase II Meeting Briefing Package to be discussed at a meeting with the FDA on May 7, 2009.